TELA Bio (TELA) Registration filing summary

Company overview and business model

• Commercial-stage medical technology business developing soft-tissue reconstruction products designed to support natural healing and limit long-term exposure to permanent synthetic materials.

• OviTex combines biologic matrices and polymer materials for hernia repair and abdominal wall reconstruction; OviTex PRS targets plastic and reconstructive surgery.

• Liora, a fully resorbable surgical mesh, received FDA 510(k) clearance in October 2026 and was the first implant fully developed in the ISO 8 certified cleanroom.

• Aroa Biosurgery is the exclusive contract manufacturer for OviTex and OviTex PRS products.

Use of proceeds and capital allocation

• Net proceeds are intended for general corporate purposes unless an offering supplement specifies otherwise; potential uses include sales and marketing, R&D, manufacturing, debt repayment, acquisitions or licensing, working capital and capex.

• Proceeds may be held as cash or temporarily invested in capital-preservation instruments until use; management retains broad allocation discretion.

Risk factors and disclosures

• Risks include continued Nasdaq listing, covenant compliance, going-concern financing needs, product acceptance, reimbursement, pricing pressure and competition from larger or new market entrants.

• Execution risks include reliance on Aroa and supply-chain expansion, sales-force growth, regulatory approvals, product development, IP protection and recruiting qualified personnel.

• Other risks include adverse safety events, procedure declines, healthcare reform, cybersecurity disruptions, macroeconomic volatility and geopolitical or trade-policy changes.

• Common stock public float was $51.9 million as of November 9, 2026; while float remains below $75.0 million, primary sales under this filing are subject to the one-third-of-float limit in any 12-month period.